GnRH拮抗剂使用时间对非多囊卵巢综合征鲜胚移植的影响

李旭; 刘林洪; 陈颖; 王雅梅; 罗银春; 任凤; 刘西茹; 陈莹

doi:10.11659/jjssx.11E022038

您当前的位置：

首页 >

文章列表页 >

GnRH拮抗剂使用时间对非多囊卵巢综合征鲜胚移植的影响

临床研究 | 更新时间：2023-04-24

- GnRH拮抗剂使用时间对非多囊卵巢综合征鲜胚移植的影响
- Effect of GnRH antagonist administration duration on fresh embryo transfer in patients with non-polycystic ovary syndrome
- 局解手术学杂志 2023年32卷第4期页码：308-312
- 作者机构：
  
  重庆医科大学附属第一医院生殖医学中心，重庆 400042
- 作者简介：
  
  陈莹，E-mail：chenying@cqmu.edu.cn.
- 基金信息：
  
  重庆市自然科学基金面上项目(cstc2021jcyj-msxmX0506);重庆医科大学未来医学青年创新团队支持计划(W130)
- DOI：10.11659/jjssx.11E022038
  中图分类号： R711.6
- 纸质出版日期：2023-04-25，
  
  收稿日期：2022-11-08，
扫描看全文
李旭,刘林洪,陈颖等.GnRH拮抗剂使用时间对非多囊卵巢综合征鲜胚移植的影响[J].局解手术学杂志,2023,32(04):308-312.

LI Xu,LIU Lin-hong,CHEN Ying,et al.Effect of GnRH antagonist administration duration on fresh embryo transfer in patients with non-polycystic ovary syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(04):308-312.
李旭,刘林洪,陈颖等.GnRH拮抗剂使用时间对非多囊卵巢综合征鲜胚移植的影响[J].局解手术学杂志,2023,32(04):308-312. DOI： 10.11659/jjssx.11E022038.

LI Xu,LIU Lin-hong,CHEN Ying,et al.Effect of GnRH antagonist administration duration on fresh embryo transfer in patients with non-polycystic ovary syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(04):308-312. DOI： 10.11659/jjssx.11E022038.

摘要

目的

探讨拮抗剂固定方案中GnRH拮抗剂使用时间对非多囊卵巢综合征（PCOS）患者鲜胚移植周期临床结局的影响

。

方法

回顾性分析于我院生殖医学中心行体外受精/卵胞浆内单精子注射（IVF/ICSI）治疗的279例不孕患者的临床资料。按照促排卵过程中GnRH拮抗剂使用时间，将患者分为拮抗剂使用时间≤3 d组和拮抗剂使用时间

3 d组。比较2组患者的基本临床特征、促排卵周期特征和鲜胚移植周期妊娠结局的差异。单因素和多因素

Logistic

回归分析鲜胚移植周期妊娠结局的影响因素。

结果

拮抗剂使用时间≤3 d组获卵率和周期取消率低于拮抗剂使用时间

3 d组（

0.05），植入率和临床妊娠率均显著高于拮抗剂使用时间

3 d组（

0.05）。2组间优胚率、第二次减数分裂中期（MⅡ）卵率、正常受精率、持续妊娠率、活产率、早期流产率差异无统计学意义(

0.05)。单因素回归分析结果显示，拮抗剂使用时间

3 d与植入率[

(95%

):0.487（0.266～0.893）

=0.020]和临床妊娠率[

(95%

):0.400（0.191～0.840）

=0.015]降低有关，但是对持续妊娠率、活产率、早期流产率无影响。多因素

Logistic

分析显示，调整了混杂变量后，拮抗剂使用时间

3 d仍是导致临床妊娠率降低的重要因素[

(95%

):0.408(0.188～0.888)

=0.024]。

结论

非PCOS患者拮抗剂固定方案中GnRH拮抗剂使用时间>3 d与鲜胚移植周期胚胎植入率和临床妊娠率降低相关。

Abstract

Objective

To investigate the effect of GnRH antagonist administration duration in the antagonist fixation protocol on the clinical outcomes of fresh embryo transfer cycle in patients with non-polycystic ovary syndrome （PCOS）.

Methods

The clinical data of 279 infertile patients who underwent in vitro fertilization/intracytoplasmic sperm injection （IVF/ICSI） in Reproductive Medicine Center of our hospital were retrospectively analyzed. According to the GnRH antagonist administration duration during ovulation induction，they were divided into the antagonist administration duration≤3 days group and the antagonist administration duration

3 days group. The basic clinical characteristics， ovulation induction cycle characteristics and pregnancy outcomes of fresh embryo transfer cycle were compared between the two groups. Univariate and multivariate

Logistic

regression analysis were used to analyze the factors influencing the pregnancy outcomes of fresh embryo transfer cycle.

Results

The oocytes retrieved rate and the cycle cancellation rate in the antagonist administration duration≤ 3 days group were significantly lower than those in the antagonist administration duration

3 days group （

0.05）， and the implantation rate and clinical pregnancy rate were significantly higher than those in the antagonist administration duration

3 days group （

0.05）. There was no statistically significant difference in the optimal embryo rate，metaphase Ⅱ（MⅡ） oocytes rate， normal fertilization rate， persistent pregnancy rate， live birth rate and early abortion rate between the two groups （

0.05）. Univariate regression analysis showed that the antagonist administration duration

3 days was associated with the decrease of the implantation rate ［

（95%

）： 0.487（0.266 to 0.893），

=0.020］ and the clinical pregnancy rate ［

（95%

）： 0.400（0.191 to 0.840），

=0.015］， but had no effect on persistent pregnancy rate， live birth rate and early abortion rate. Multivariate

Logistic

analysis showed that after adjusting for confounding variables， antagonist administration duration

3 days was still an important factor in reducing the clinical pregnancy rate ［

（95%

）： 0.408（0.188 to 0.888），

=0.024］.

Conclusion

In the antagonist fixation protocol for non-PCOS patients， the antagonist administration duration>3 days is associated with the decrease of embryo implantation rate and clinical pregnancy rate in the fresh embryo transfer cycle.

关键词

拮抗剂方案卵巢刺激临床妊娠体外受精鲜胚移植非多囊卵巢综合征

Keywords

antagonist protocolovarian stimulationclinical pregnancyin vitro fertilizationfresh embryo transfernon-polycystic ovary syndrome

references

Depalo R，Trerotoli P，Chincoli A，et al.Endogenous luteinizing

hormone concentration and IVF outcome during ovarian stimulation in fixed versus flexible GnRH antagonist protocols：An RCT［J］.Int J

Reprod Biomed，2018，16（3）：175-182

Al-Inany HG，Youssef MA，Ayeleke RO，et al.Gonadotrophin-

releasing hormone antagonists for assisted reproductive technology［J］.Cochrane Database Syst Rev，2016，4：Cd001750.doi：10.1002/14651858.CD001750.pub4http://dx.doi.org/10.1002/14651858.CD001750.pub4.

Copperman AB，Benadiva C.Optimal usage of the GnRH antagonists：a review of the literature［J］.Reprod Biol Endocrinol，2013，11：20.doi：10.1186/1477-7827-11-20http://dx.doi.org/10.1186/1477-7827-11-20.

Tarlatzis BC，Fauser BC，Kolibianakis EM，et al.GnRH antagonists in ovarian stimulation for IVF［J］.Hum Reprod Update，2006，12（4）：333-340.doi：10.1093/humupd/dml001http://dx.doi.org/10.1093/humupd/dml001.

Albano C，Smitz J，Camus M，et al.Comparison of different doses of

gonadotropin⁃releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation［J］.Fertil Steril，1997，67（5）：917-922.doi：10.1016/s0015-0282（97）81407-0http://dx.doi.org/10.1016/s0015-0282（97）81407-0.

Kolibianakis EM，Albano C，Kahn J，et al.Exposure to high levels of

luteinizing hormone and estradiol in the early follicular phase of

gonadotropin⁃releasing hormone antagonist cycles is associated with a reduced chance of pregnancy［J］.Fertil Steril，2003，79（4）：873-880.doi：10.1016/s0015-0282（02）04920-8http://dx.doi.org/10.1016/s0015-0282（02）04920-8.

Kaponis A，Chronopoulou E，Decavalas G.The curious case of premature luteinization［J］.J Assist Reprod Genet，2018，35（10）：1723-1740.doi：10.1007/s10815-018-1264-8http://dx.doi.org/10.1007/s10815-018-1264-8.

Meng Y，Guo Y，Qian Y，et al.Effects of GnRH antagonist on endometrial protein profiles in the window of implantation［J］.Proteomics，2014，14（20）：2350-2359.doi：10.1002/pmic.201400145http://dx.doi.org/10.1002/pmic.201400145.

Luo Y，Liu S，Su H，et al.Low serum lh levels during ovarian stimulation with gnrh antagonist protocol decrease the live birth rate

after fresh embryo transfers but have no impact in freeze⁃all cycles［J］.Front Endocrinol （Lausanne），2021，12：640047.doi：10.3389/fendo.2021.640047http://dx.doi.org/10.3389/fendo.2021.640047.

Benmachiche A，Benbouhedja S，Zoghmar A，et al.Low LH level on the day of GnRH agonist trigger is associated with reduced ongoing pregnancy and live birth rates and increased early miscarriage rates following IVF/ICSI treatment and fresh embryo transfer［J］.Front

Endocrinol （Lausanne），2019，10：639.doi：10.3389/fendo. 2019.00639http://dx.doi.org/10.3389/fendo.2019.00639.

Eftekhar M，Hoseini M，Tabibnejad N.Is there a relationship between luteinizing hormone levels and ART outcome in GnRH antagonist

protocols？ A retrospective cross⁃sectional study［J］.Indian J Endocrinol Metab，2021，25（6）：563-568.doi：10.4103/ijem.ijem_331_21http://dx.doi.org/10.4103/ijem.ijem_331_21.

Zikopoulos K，Kolibianakis EM，Camus M，et al.Duration of gonadotropin⁃releasing hormone antagonist administration does not affect the outcome of subsequent frozen⁃thawed cycles［J］.Fertil Steril，2004，

81（2）：473-475.doi：10.1016/j.fertnstert.2003.08.009http://dx.doi.org/10.1016/j.fertnstert.2003.08.009.

Detti L，Ambler DR，Yelian FD，et al.Timing and duration of use of GnRH antagonist down⁃regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes［J］.J Assist Reprod Genet，2008，25（5）：177-181.doi：10.1007/s10815-008-9217-2http://dx.doi.org/10.1007/s10815-008-9217-2.

Al⁃Inany H，Aboulghar M.Gonadotrophin⁃releasing hormone antagonists for assisted conception［J］.Cochrane Database Syst Rev， 2001（4）：Cd001750.doi：10.1002/14651858.Cd001750http://dx.doi.org/10.1002/14651858.Cd001750.

Ludwig M，Katalinic A，Banz C，et al.Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF：results of a prospective，randomized study［J］.Hum Reprod，2002，17（11）：2842-2845.doi：10.1093/humrep/17.11.2842http://dx.doi.org/10.1093/humrep/17.11.2842.

Zhao Y，Lian F，Xiang S，et al.Effects of half⁃dose and full⁃dose GnRH antagonists on IVF⁃ET outcomes：a retrospective study［J］.BMC Pregnancy Childbirth，2021，21（1）：727.doi：10.1186/s12884-021-04176-8http://dx.doi.org/10.1186/s12884-021-04176-8.

Feng L，Fan R，Jiang A，et al.The effect of flexible low⁃dose GnRH antagonist on pregnancy outcome in the fresh embryo transfer cycle of IVF⁃ET：a randomized controlled trial［J］.Reprod Biol Endocrinol，2022，20（1）：55.doi：10.1186/s12958-022-00927-0http://dx.doi.org/10.1186/s12958-022-00927-0.

Zhang D，Zhang D，Sun Z，et al.The effect of a transient premature

luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin⁃releasing hormone

antagonist flexible protocol［J］.Gynecol Endocrinol，2020，36（6）：550-553.doi：10.1080/09513590.2019.1683730http://dx.doi.org/10.1080/09513590.2019.1683730.

Zhou R，Zhang X，Dong M，et al.Association between endogenous LH level prior to progesterone administration and live birth rate in artificial frozen⁃thawed blastocyst transfer cycles of ovulatory women［J］.Hum Reprod，2021，36（10）：2687-2696.doi：10.1093/humrep/deab172http://dx.doi.org/10.1093/humrep/deab172.

Al-Inany H，Aboulghar M.GnRH antagonist in assisted reproduction：a Cochrane review［J］.Hum Reprod，2002，17（4）：874-885.doi：10.1093/humrep/17.4.874http://dx.doi.org/10.1093/humrep/17.4.874.

Chang YL，Hsieh YY，Tsai HD.Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist （cetrorelix） on ovarian hyperstimulation in lower-weight Asian women［J］.Taiwan J Obstet Gynecol，2006，45（4）：317-320.doi：10.1016/s1028-4559（09）60250-3http://dx.doi.org/10.1016/s1028-4559（09）60250-3.

Broughton DE，Moley KH.Obesity and female infertility：potential

mediators of obesity's impact［J］.Fertil Steril，2017，107（4）：840-847.doi：10.1016/j.fertnstert.2017.01.017http://dx.doi.org/10.1016/j.fertnstert.2017.01.017.

Jungheim ES，Moley KH.Current knowledge of obesity's effects in the pre⁃ and periconceptional periods and avenues for future research［J］.Am J Obstet Gynecol，2010，203（6）：525-530.doi：10.1016/j.ajog.2010.06.043http://dx.doi.org/10.1016/j.ajog.2010.06.043.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据